Table 3.

Comparison of patients with no demonstrable inhibitor with those who had strong inhibitors

OutcomeNo inhibitor (<1 BU/mL) (n = 27)>2 BU/mL (n = 30)P
No.%MedianRangeNo.%MedianRange
Platelets × 103/µL*   9 4-101   11 5-63 .12 
Hematocrit, %*   20 14-33   22 13-28 .69 
Creatinine, mg/dL   1.3 0.7-6.8   1.35 0.8-5.5 .86 
LDH, U/L   1207 432-2962   1500 274-3909 .36 
Severe neurologic abnormalities 12 44   18 60   .29 
PEX   12 2-71   11 1-79 .79 
Exacerbation 9 33   16/29* 55   .12 
Survival 25 93   23 77   .15 
Relapse 8/25 32   10/23 44   .55 
OutcomeNo inhibitor (<1 BU/mL) (n = 27)>2 BU/mL (n = 30)P
No.%MedianRangeNo.%MedianRange
Platelets × 103/µL*   9 4-101   11 5-63 .12 
Hematocrit, %*   20 14-33   22 13-28 .69 
Creatinine, mg/dL   1.3 0.7-6.8   1.35 0.8-5.5 .86 
LDH, U/L   1207 432-2962   1500 274-3909 .36 
Severe neurologic abnormalities 12 44   18 60   .29 
PEX   12 2-71   11 1-79 .79 
Exacerbation 9 33   16/29* 55   .12 
Survival 25 93   23 77   .15 
Relapse 8/25 32   10/23 44   .55 

Functional inhibitor activity was measured by the FRET assay. The 20 patients with an intermediate-strength inhibitor titer (1-2 BU/mL) were not included in this analysis.

*

One patient failed to respond and therefore could not be evaluated for exacerbation.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal